Ovid Therapeutics, Inc. (OVID)

1.835 +0.02 (+1.38%) USD  |  NASDAQ  |  Dec 24, 10:36
More

Ovid Therapeutics SG&A Expense (TTM): 22.56M for Sept. 30, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for OVID.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
AnaptysBio, Inc. 45.14M
Ionis Pharmaceuticals, Inc. 351.68M
MannKind Corp. 195.42M
Cassava Sciences, Inc. 68.06M
Cidara Therapeutics, Inc. 28.09M